{
  "id": 10459769,
  "title": "CMS pumps $51M into rural Texas to fight diabetes and obesity",
  "url": "https://urgent.news/2026/09/28/cms-pumps-51m-into-rural-texas-to-fight-diabetes-and-obesity",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T14:10:24.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/cms-pumps-51m-into-rural-texas-to-fight-diabetes-and-obesity-93CH-4920665"
  },
  "original_language": "en",
  "account": "The federal government has allocated $51 million to 68 rural hospital districts in Texas to establish and enhance chronic disease prevention programs, focusing on diabetes, cardiovascular disease, respiratory illness, and obesity. This represents the initial segment of Texas's $281 million allocation for the inaugural year of the Rural Health Transformation Program (RHTP), established by the Working Families Tax Cuts Act. The funding, approximately $750,000 per district, represents just a fraction of the broader RHTP's $50 billion national budget and the $1.4 billion five-year investment earmarked for Texas alone. The RHTP explicitly funds telehealth expansion, remote patient monitoring, and digital health infrastructure, areas in which VSee Health, a telehealth company, is a direct beneficiary. The RHTP is the largest federal rural health investment in over two decades, according to CMS. States such as Arkansas, Delaware, and South Dakota have also received RHTP grants, with funds dedicated to chronic disease, maternal health, mobile care, and behavioral healthcare respectively. The program aims to keep rural hospitals operational, expand telehealth access, and encourage medical professionals' recruitment and retention. Rep. August Pfluger emphasized the positive impact on communities with adequate hospital resources. CMS Administrator Dr. Mehmet Oz highlighted that these investments prioritize patients, driving lasting improvements and healthcare expansion for rural communities. The RHTP's focus on diabetes, obesity, cardiovascular disease, and respiratory illness aligns with the commercial interests of several publicly traded companies, including Eli Lilly, Novo Nordisk, DexCom, Insulet, ResMed, Teladoc, and Medtronic. The ultimate beneficiaries will be determined by the technology vendors selected by the hospital districts over a 12-24 month period. Additionally, a proposed 2027 Medicare rule change could significantly impact the revenue models of device manufacturers by increasing reimbursement rates for remote patient monitoring and therapeutic monitoring. Investors in companies like Lilly, Novo Nordisk, DexCom, and Teladoc should monitor forthcoming state-level grant announcements and CMS rulemaking activities to assess the speed at which federal rural health spending converts into commercial revenue.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}